Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a highly aggressive malignancy with pronounced immunogenicity, exhibiting rapid proliferation and immune cell infiltration into the tumor microenvironment. TNBC’s heterogeneity poses challenges to immunological treatments, inducing resistance mechanisms in the...

Full description

Bibliographic Details
Main Authors:	Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Biomedicines
Subjects:	resistance triple-negative breast cancer PD-1/PD-L1/CTLA-4 TME
Online Access:	https://www.mdpi.com/2227-9059/12/2/369

Similar Items

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
by: Huimei Yi, et al.
Published: (2021-05-01)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
by: Yuanfang Xin, et al.
Published: (2021-11-01)

The clinical promise of immunotherapy in triple-negative breast cancer
by: Vikas P, et al.
Published: (2018-12-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
by: Dan Qiu, et al.
Published: (2022-01-01)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
by: Ji-Yeon Kim, et al.
Published: (2023-03-01)

Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
by: Lijun Peng, et al.
Published: (2022-09-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
by: Hongjing Zang, et al.
Published: (2020-04-01)

Skin Manifestation Induced by Immune Checkpoint Inhibitors
by: Yamamoto T
Published: (2022-05-01)

Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
by: Douglas B. Johnson, et al.
Published: (2019-05-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
by: Gabriel Surdacki, et al.
Published: (2019-03-01)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
by: Carlo Genova, et al.
Published: (2022-01-01)

TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
by: Neslihan Cabioglu, et al.
Published: (2021-04-01)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by: Rita Balsano, et al.
Published: (2023-03-01)

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer
by: HUANG Shifen, et al.
Published: (2021-01-01)

Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
by: Katerina S Grechukhina, et al.
Published: (2019-09-01)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
by: Ming Yi, et al.
Published: (2018-03-01)

Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review
by: Szonja Anna Kovács, et al.
Published: (2022-05-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

Expression of PD-L1 in triple negative breast cancer
by: Gina James Keorges
Published: (2023-03-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
by: Deniz Can Guven, et al.
Published: (2022-10-01)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
by: Jun Gong, et al.
Published: (2019-03-01)

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
by: Benjamin Rolles, et al.
Published: (2021-08-01)

Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors
by: Elisabetta Maria Abenavoli, et al.
Published: (2023-11-01)

Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
by: Norah A. Alturki
Published: (2023-06-01)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2022-11-01)

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
by: Vicenç Ruiz de Porras, et al.
Published: (2021-04-01)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
by: Jinyao Wu, et al.
Published: (2023-01-01)

Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?
by: Elissavet Ntemou, et al.
Published: (2024-03-01)

The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma
by: Jihyun An, et al.
Published: (2022-03-01)

Immune Checkpoints and Innovative Therapies in Glioblastoma
by: Massimo Romani, et al.
Published: (2018-10-01)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
by: Gwenyth J. Joseph, et al.
Published: (2023-12-01)

Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model
by: Yi-Ru Pan, et al.
Published: (2020-11-01)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Chengdi Wang, et al.
Published: (2019-07-01)